Compare RSKD & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSKD | CTMX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.3M | 596.2M |
| IPO Year | N/A | N/A |
| Metric | RSKD | CTMX |
|---|---|---|
| Price | $4.45 | $5.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $5.91 | ★ $8.86 |
| AVG Volume (30 Days) | 573.6K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $9.41 | N/A |
| P/E Ratio | ★ N/A | $22.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.94 | $0.40 |
| 52 Week High | $5.86 | $6.35 |
| Indicator | RSKD | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 50.40 |
| Support Level | $4.33 | $5.20 |
| Resistance Level | $4.53 | $5.65 |
| Average True Range (ATR) | 0.15 | 0.49 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 75.00 | 21.21 |
Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer & Crypto, Tickets & Travel, Electronics, Home, Fashion & Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.